Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
In Immunome’s own words, from its job postings.
| Team | Open roles | Typical posted pay (US) |
|---|---|---|
| Ops | 8 | $177K–$238K |
| Engineering | 1 | — |
| Finance | 1 | — |
Based on 10 US job postings from Immunome that disclose pay, the median posted range is $177K–$238K base salary. Ranges come straight from the job descriptions (pay-transparency disclosures), not from self-reported surveys.